IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -3.43 SEK | -55.91% |
| 2022 | -2.20 SEK | -320.0% |
| 2021 | 1.00 SEK | 151.81% |
| 2020 | -1.93 SEK | 17.17% |
| 2019 | -2.33 SEK | -22.63% |
| 2018 | -1.90 SEK | -15.85% |
| 2017 | -1.64 SEK | 1.2% |
| 2016 | -1.66 SEK | -238.78% |
| 2015 | -0.49 SEK | -476.92% |
| 2014 | 0.13 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.14 SEK | 81.33% |
| 2024 Q3 | -0.61 SEK | -335.71% |
| 2024 Q1 | -0.75 SEK | -11.94% |
| 2023 Q2 | -0.87 SEK | 24.35% |
| 2023 Q4 | -0.67 SEK | 9.46% |
| 2023 FY | - SEK | -55.91% |
| 2023 Q3 | -0.74 SEK | 14.94% |
| 2023 Q1 | -1.15 SEK | -79.69% |
| 2022 Q3 | -0.46 SEK | 13.21% |
| 2022 Q2 | -0.53 SEK | 7.02% |
| 2022 Q1 | -0.57 SEK | -26.67% |
| 2022 FY | - SEK | -320.0% |
| 2022 Q4 | -0.64 SEK | -39.13% |
| 2021 Q2 | -0.51 SEK | -30.77% |
| 2021 FY | - SEK | 151.81% |
| 2021 Q4 | -0.45 SEK | -119.15% |
| 2021 Q1 | -0.39 SEK | 2.5% |
| 2021 Q3 | 2.35 SEK | 560.78% |
| 2020 Q2 | -0.54 SEK | -28.57% |
| 2020 Q3 | -0.55 SEK | -1.85% |
| 2020 Q4 | -0.40 SEK | 27.27% |
| 2020 FY | - SEK | 17.17% |
| 2020 Q1 | -0.42 SEK | 35.38% |
| 2019 FY | - SEK | -22.63% |
| 2019 Q4 | -0.65 SEK | -22.64% |
| 2019 Q3 | -0.53 SEK | 29.33% |
| 2019 Q2 | -0.75 SEK | -66.67% |
| 2019 Q1 | -0.45 SEK | 2.17% |
| 2018 Q1 | -0.45 SEK | -21.62% |
| 2018 FY | - SEK | -15.85% |
| 2018 Q4 | -0.46 SEK | -510.08% |
| 2018 Q2 | -0.65 SEK | -44.44% |
| 2018 Q3 | -0.08 SEK | 88.4% |
| 2017 Q1 | -0.40 SEK | 31.03% |
| 2017 Q2 | -0.30 SEK | 25.0% |
| 2017 Q3 | -0.59 SEK | -96.67% |
| 2017 Q4 | -0.37 SEK | 37.29% |
| 2017 FY | - SEK | 1.2% |
| 2016 Q1 | -0.51 SEK | 0.0% |
| 2016 FY | - SEK | -238.78% |
| 2016 Q3 | -0.42 SEK | -61.54% |
| 2016 Q2 | -0.26 SEK | 49.02% |
| 2016 Q4 | -0.58 SEK | -38.1% |
| 2015 FY | - SEK | -476.92% |
| 2014 FY | - SEK | 0.0% |